

Enhanced Recovery After Surgery in Emergency Resection for Obstructive Colorectal Cancer: A Systematic Review and Meta-analysis

Varut Lohsiriwat (■ bolloon@hotmail.com)

Mahidol University Faculty of Medicine Siriraj Hospital https://orcid.org/0000-0002-2252-9509

Romyen Jitmungngan

Golden Jubilee Medical Center, Mahidol University

Weeraput Chadbunchachai

Khon Kaen University Faculty of Medicine

Patompong Ungprasert

Mahidol University Faculty of Medicine Siriraj Hospital

Research article

Keywords: enhanced recovery after surgery, colon cancer, rectum cancer, obstruction, emergency, systematic review, patient outcome

Posted Date: April 1st, 2020

DOI: https://doi.org/10.21203/rs.3.rs-20540/v1

License: © (1) This work is licensed under a Creative Commons Attribution 4.0 International License.

Read Full License

Version of Record: A version of this preprint was published at International Journal of Colorectal Disease on June 22nd, 2020. See the published version at https://doi.org/10.1007/s00384-020-03652-5.

Abstract

Background: Enhanced recovery after surgery (ERAS) improves outcomes after elective colorectal operations. Whether it is beneficial for emergency colorectal surgery is unclear. This study aimed to systematically review and summarize evidence from all studies comparing ERAS versus conventional care in patients having emergency colectomy and/or proctectomy for obstructive colorectal cancer.

Methods: EMBASE and MEDLINE from inception to October 2019 were systematically searched. Any studies comparing our primary outcome of interest (length of hospitalization) among patients having emergency resection for obstructive colorectal cancer who received ERAS versus conventional care were selected. Primary outcome was length of hospitalization. Secondary outcomes were gastrointestinal recovery, postoperative complication, 30-day readmission and mortality, and time to start adjuvant therapy.

Results: Three cohort studies with 818 participants (418 received ERAS and 400 received conventional care) were included. Length of hospitalization (mean reduction 3.07 days; 95% CI, - 3.91 to -2.23) and risk of overall postoperative complication (risk ratio 0.78; 95% CI, 0.63 to 0.97) were significantly lower in ERAS than in conventional care. ERAS was also associated with quicker time to gastrointestinal recovery, a lower incidence of ileus, and a shorter interval between operation and commence of adjuvant chemotherapy. There was no significant difference in the rates of anastomotic leakage, re-operation, readmission and mortality within 30 days after an operation between groups.

Conclusions: ERAS had advantages over conventional care in patients undergoing emergency resection for obstructive colorectal cancer - including a shorter length of hospitalization, a lower incidence of complication and quicker gastrointestinal recovery.

Background

Emergency colectomy and/or proctectomy are among the top three most common emergency laparotomies performed in the United Kingdom [1] and the United States [2] – with a high rate of 30-day postoperative morbidity (ranging from 26.8–69.2%) [2] and mortality (ranging from 8.8–31.6%) [1]. Acute colonic obstruction is a common manifestation of colorectal cancer (CRC) that is responsible for 15–30% of initial clinical presentation [3]. Emergency resection of the tumor with or without anastomosis remains the mainstay treatment for obstructive CRC - especially right-sided colon cancer, left-sided colonic obstruction that is not eligible for colonic stenting, and CRC with suspected bowel perforation [3]. However, postoperative morbidities and mortalities following surgical treatment for obstructive CRC are high [4] - even performed by colorectal surgeons [5].

Enhanced recovery after surgery (ERAS) minimizes patient's surgical stress responses, optimizes their function, and enables rapid recovery [6]. Several meta-analyses of randomized controlled trials of elective colorectal operations have consistently found the advantages of ERAS over perioperative conventional care - including shorter hospitalization and fewer complications [7–9]. However, only few studies

examining the benefits of ERAS in emergency colorectal surgery were available and their results were inconsistent [10–12].

To our knowledge, there is no meta-analysis evaluating the benefits of ERAS protocol for colorectal surgery in an emergency setting. Our study hypothesized that ERAS could facilitate patient's discharge and improves surgical outcomes after emergency colectomy and/or proctectomy for obstructive CRC.

Materials And Methods

This systematic review and meta-analysis was performed in accordance to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement [13].

Search strategy

Published literature indexed in EMBASE and MEDLINE from inception to October 2019 was independently searched by three investigators. Search terms for EMBASE were 'enhanced recovery after surgery'/exp OR 'enhanced recovery after surgery', and for MEDLINE were enhanced recovery after surgery.mp. OR exp enhanced recovery after surgery/. No language limitation was applied. References of the included studies were further reviewed to identify any additional suitable studies that may be missed by the aforementioned search strategy.

Inclusion criteria

Studies that were eligible for this meta-analysis must be cohort studies that enrolled patients having emergency colectomy and/or proctectomy for obstructive CRC. One group of patients must follow ERAS pathway while the other group must receive conventional care. The eligible studies must report the primary outcome, which is the average length of hospital stay of both groups along with standard deviation (SD). Secondary outcomes, including time to pass stool, time to resume regular diet, time to start adjuvant chemotherapy, rate of postoperative ileus, rate of leakage, rate of complications, reoperation, readmission and mortality within 30 days after an operation, were extracted and analyzed but were not part of the inclusion criteria. Study eligibility was independently evaluated by the three investigators with differing opinions resolved by group discussion. The Newcastle-Ottawa quality assessment scale for cohort studies was used to determine the quality of each study [14].

Data extraction

The three investigators independently extracted data using a standardized form containing the primary outcome, secondary outcomes and characteristics of the study which included, country where the study was conducted, study period, year of publication, number of cases, age and gender of participants, location of obstructive CRC and types of surgery performed in that study. Any discrepancies were reviewed and corrected according to the original reports.

Statistical analysis

Mean length of hospital stay, time to first bowel movement, time to tolerate solid food, and time to start adjuvant chemotherapy along with SD of participants in both groups were extracted from each study and the mean difference (MD) was calculated. Pooled MD was then calculated by combining MDs of each study using random-effects model. If the study provided median and interquartile range, median would be used as an estimate for mean and SD would be estimated from interguartile range divided by 1.35.

Relative risk (RR) of postoperative ileus, leakage, complications, reoperation, readmission and mortality were calculated using rate of that event in each group. RRs from all studies included were added together to calculate pooled RR using the DerSimonian and Laird random-effect model [15].

The heterogeneity of the MDs and RRs across studies was calculated using the Q statistic (I^2 statistics) where I^2 value of 0–25%, 26-50%, 51-75% and 76-100% means insignificant, low, moderate and high heterogeneity, respectively [16]. Visual inspection of funnel plots would be used to determine publication bias if enough eligible studies were identified. Statistical analysis was done using Review Manager 5.3 software from the Cochrane Collaboration (London, United Kingdom).

Results

Some 4236 potentially relevant articles (2646 from EMBASE and 1590 from MEDLINE) were identified. After removal of 1104 duplicated articles, 3132 articles underwent title and abstract review. At this stage, 3098 articles were excluded because they did not meet our inclusion criteria – leaving the remaining 34 articles retrieved for a complete review. After reviewing full-length articles, 31 articles were excluded because of no emergency cases included (n=11), duplication (n=8), conference abstract (n=8), and no report of the outcome of interest (n=4). Details of the last four studies are as follows; one study compared outcome between patients underwent ERAS after emergency colorectal surgery who did and did not have complicated intraabdominal infection [17], one examined whether ERAS improved outcomes following emergency major abdominal surgery [18], one evaluated the feasibility of early postoperative mobilization after colorectal surgery under an ERAS protocol [19], and one determined predictors of nasogastric tube reinsertion following emergency operations for obstructive CRC [20]. Finally, three cohort studies [10-12] with 818 participants (418 underwent ERAS and 400 underwent conventional care) fulfilled the inclusion criteria and were included into the meta-analysis. Study flow is shown in **Figure 1**. Characteristics of the included studies are summarized in **Table 1**.

Length of hospital stay

Length of hospital stay was significantly shorter in patients receiving ERAS than that of those receiving conventional care with the pooled MD of -3.07 days (95% CI, -3.91 to -2.23). Heterogeneity among studies was negligible (I^2 of 0%) (Figure 2a).

Complications

The rate of postoperative complication was significantly lower in patients receiving ERAS than that of those receiving conventional care with the pooled RR of 0.78 (95% CI, 0.63 to 0.97). Heterogeneity among studies was negligible (I^2 of 0%) (Figure 2b).

30-day readmission and mortality

Rates of 30-day readmission and mortality were comparable between the two groups - with the pooled RR of 0.91 (95% CI, 0.54 to 1.51) and 0.79 (95% CI, 0.11 to 5.38), respectively. Heterogeneity among studies was negligible (I^2 of 0% and 24%, respectively) (**Figure 2c and Figure 2d**).

Time to gastrointestinal recovery

Time to pass flatus was significantly shorter in patients receiving ERAS than that of those receiving conventional care with the pooled MD of -1.39 days (95% CI, -1.52 to -1.25). The between-study heterogeneity was negligible (I^2 of 0%) (Figure 3a). Time to first defecation was also significantly shorter in patients receiving ERAS - with the pooled MD of -0.73 days (95% CI, -1.40 to -0.06), but heterogeneity between studies was moderate (I^2 of 73%) (Figure 3b). A significantly shorter time to resume regular diet was found in the ERAS group with the pooled MD of -2.39 days (95% CI, -2.62 to -2.15), and the between study heterogeneity was negligible (I^2 of 0%) (Figure 3c).

Postoperative ileus

The rate of postoperative ileus was significantly lower in patients receiving ERAS than that of those receiving conventional care with the pooled RR of 0.55 (95% CI, 0.33 to 0.91). Heterogeneity among studies was negligible (I^2 of 0%) (Figure 4a).

Anastomotic leakage

Rate of anastomotic leakage was comparable between the two groups - with the pooled RR of 0.96 (95% CI, 0.25 to 3.65). The between-study heterogeneity was negligible (I^2 of 0%) (Figure 4b).

Re-operation

Rate of 30-day re-operation was comparable between the two groups - with the pooled RR of 0.78 (95% CI, 0.32 to 1.92). The between-study heterogeneity was negligible (I^2 of 0%) (Figure 4c).

Time to start adjuvant chemotherapy

Patient receiving ERAS had a significantly shorter time to start adjuvant chemotherapy, with the pooled MD of -12.05 days (95% CI, -14.76 to -9.35) and negligible between-study heterogeneity (I^2 of 0%) (Figure 5).

Evaluation for publication bias

Due to a limited number of eligible studies, funnel plot was not created for evaluating publication bias.

Discussion

This systematic review and meta-analysis of ERAS in emergency resection for obstructive CRC incorporated 3 cohort studies that included 418 cases with ERAS and 400 cases with conventional care. This meta-analysis indicated that patients receiving ERAS had a significantly shorter length of hospital stay, quicker time to gastrointestinal recovery, lower incidence of postoperative ileus and overall complications, and shorter time to initiate adjuvant chemotherapy.

The approximately 3-day reduction in hospital stay and a 22% decreased risk of overall complications observed in this study are comparable to the benefit of ERAS in the setting of elective colorectal operation. A systematic review and meta-analysis of 13 randomized controlled trials including 1,910 patients undergoing elective major colorectal operations showed that ERAS decreased length of hospitalization by 2.4 days and decreased risk of overall complications by 29% compared with conventional care [8]. Another systematic review and meta-analysis of 25 trials including 3,787 patients undergoing elective laparoscopic or open surgery for malignant and benign colorectal diseases [9] found a 2.6 days reduction of hospital stay and a 34% decrease in risk of perioperative complications compared with conventional care. All of these suggest that benefit of ERAS is seen across different surgical approaches and indications.

There was no significant difference in the rate of anastomotic leakage and re-operation. Therefore, the benefit of early resumption of solid food and accelerated gastrointestinal recovery by ERAS does not come at the expense of increased anastomotic leakage. In fact, it has been shown that implementation of ERAS [21] and early consumption of solid food [22] can facilitate the return of bowel function and minimize the rate of prolonged ileus following elective colorectal operation.

The current study also demonstrated that patients in ERAS pathway had an approximately 2 weeks shorter time interval between operation and starting date of adjuvant chemotherapy (which is usually indicated in patients with obstructive CRC [23]). Time to adjuvant therapy is a potential mid-term outcome measure that could be used to determine patient's overall recovery and performance [24], as it has been shown that delayed commencement of adjuvant chemotherapy (especially > 8 week) is linked to a worse overall survival in patients with CRC. One possible explanation of this is that early initiation of postoperative chemotherapy may prevent tumor growth or recurrence [25]. Since postoperative complications are one of the major reasons for delayed adjuvant chemotherapy [26], the benefits of ERAS, therefore, may go beyond just the immediate postoperative period.

It is worth noting that all three cohort studies included in this meta-analysis used their 'modified' ERAS pathway [10–12] as there is still no standard ERAS Society guideline or recommendation for emergency colorectal surgery. Thus, it remains unknown which interventions of ERAS pathway are beneficial and should be recommended in clinical practice. Obviously, some interventions, such as preoperative nutritional support and carbohydrate loading, are not advisable for patients with acute malignant colonic

obstruction. However, most ERAS interventions recommended for elective colorectal operation appear to be applicable to emergency surgery as well [27].

It should also be noted that patients with obstructive CRC with colonic perforation were not included in any of the included studies. In fact, a recent study of ERAS in emergency colorectal resection for various colorectal conditions, including obstructive CRC and fecal peritonitis, suggested that patients with bowel perforation had a lower rate of ERAS compliance and a higher rate of complications than those without [17]. Further investigations are still needed to determine whether ERAS could provide similar benefits to these patients.

A major strength of this study is the unique advantage of the systematic review and meta-analysis technique that offers comprehensive evaluation of all available evidence. The study was conducted in accordance to the PRISMA guideline to ensure the highest standard of the analyses and data on several outcomes were analyzed. Nonetheless, there are some limitations that should be acknowledged.

First, only three cohort studies were included and they were all retrospective in nature. This may increase the risk for both performance and measurement bias – although a matching analysis was performed in two of the three studies [10, 12] and one study was a relatively large multicenter trial [12]. It is noteworthy that, to date, there is no published or registered randomized controlled trial that compares outcomes between ERAS versus conventional care in emergency setting for malignant colonic obstruction (http://www.clinicaltrials.gov/ClinicalTrials.gov; accessed on 25 March 2020). It may be difficult, or even ethical [27], to conduct such randomized controlled trials because ERAS has increasingly become a standard of surgical care [6]. As a result, the present study might be the best available evidence to support that ERAS can be applied effectively and safely in the setting of emergency resection for obstructive CRC - similar to elective colorectal operations [7–9].

Second, the role of compliance on the benefit of ERAS is not known as none of the included studies investigated the impact of compliance on surgical outcomes although a large international registry of patients undergoing elective CRC resection [28] and a small cohort of patients undergoing emergency surgery for obstructive CRC and colonic perforation [17] have demonstrated that higher compliance to ERAS was associated with better outcomes. Similarly, the impact of laparoscopy is not known because only one study in this meta-analysis included patients who underwent laparoscopic surgery in their 'modified' ERAS protocol (and only 4 patients were included) [11]. Although studies of elective colorectal surgery found a significant benefit of laparoscopy combined with ERAS with markedly improved surgical outcomes and patient recovery [28, 29], the benefit of laparoscopy may not be translated into emergency setting as the conversion rate is still relatively high [27].

Conclusions

This systematic review and meta-analysis of 3 non-randomized observational studies incorporating 818 patients undergoing emergency resection for obstructive CRC found that, in comparison with conventional care, ERAS pathway was associated with a shorter length of hospital stay, quicker time to

bowel function recovery, a lower incidence of postoperative ileus and overall complications, and a shorter time to start adjuvant chemotherapy. Anastomotic leakage, re-operation, 30-day readmission and mortality were comparable between the groups.

Declarations

Ethics approval and consent to participation

Not applicable. (The identity of the subjects under this systematic review and meta-analysis was omitted and anonymized.)

Consent for publication

Not applicable.

Availability of data and materials

All data analyzed during this study are included in this published article.

Completing interests

The authors declare that they have no completing interests.

Funding

None

Authors' contribution

VL and PU outlined the content. VL, RJ and WC reviewed literature and collected data. VL and PU analyzed data and wrote the manuscript. RJ and WC critically reviewed the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

References

- 1. Barrow E, Anderson ID, Varley S, Pichel AC, Peden CJ, Saunders DI, et al. Current UK practice in emergency laparotomy. Ann R Coll Surg Engl. 2013;95:599-603.
- 2. Scott JW, Olufajo OA, Brat GA, Rose JA, Zogg CK, Haider AH, et al. Use of National Burden to Define Operative Emergency General Surgery. JAMA Surg. 2016;151:e160480.

- 3. Pisano M, Zorcolo L, Merli C, Cimbanassi S, Poiasina E, Ceresoli M, et al. 2017 WSES guidelines on colon and rectal cancer emergencies: obstruction and perforation. World J Emerg Surg. 2018;13:36.
- 4. Aquina CT, Becerra AZ, Xu Z, Boscoe FP, Schymura MJ, Noyes K, et al. Nonelective colon cancer resection: A continued public health concern. Surgery. 2017;161:1609-18.
- 5. Kulaylat AS, Pappou E, Philp MM, Kuritzkes BA, Ortenzi G, Hollenbeak CS, et al. Emergent Colon Resections: Does Surgeon Specialization Influence Outcomes? Dis Colon Rectum. 2019;62:79-87.
- 6. Ljungqvist O, Scott M, Fearon KC. Enhanced Recovery After Surgery: A Review. JAMA Surg. 2017;152:292-8.
- 7. Varadhan KK, Neal KR, Dejong CH, Fearon KC, Ljungqvist O, Lobo DN. The enhanced recovery after surgery (ERAS) pathway for patients undergoing major elective open colorectal surgery: a meta-analysis of randomized controlled trials. Clin Nutr. 2010;29:434-40.
- 8. Zhuang CL, Ye XZ, Zhang XD, Chen BC, Yu Z. Enhanced recovery after surgery programs versus traditional care for colorectal surgery: a meta-analysis of randomized controlled trials. Dis Colon Rectum. 2013;56:667-78.
- 9. Greer NL, Gunnar WP, Dahm P, Lee AE, MacDonald R, Shaukat A, et al. Enhanced recovery protocols for adults undergoing colorectal surgery: a systematic review and meta-analysis. Dis Colon Rectum. 2018;61:1108-18.
- 10. Lohsiriwat V. Enhanced recovery after surgery vs conventional care in emergency colorectal surgery. World J Gastroenterol. 2014;20:13950-5.
- 11. Shida D, Tagawa K, Inada K, Nasu K, Seyama Y, Maeshiro T, et al. Modified enhanced recovery after surgery (ERAS) protocols for patients with obstructive colorectal cancer. BMC Surg. 2017;17:18.
- 12. Shang Y, Guo C, Zhang D. Modified enhanced recovery after surgery protocols are beneficial for postoperative recovery for patients undergoing emergency surgery for obstructive colorectal cancer: A propensity score matching analysis. Medicine (Baltimore). 2018;97:e12348.
- 13. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
- 14. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2020. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
- 15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
- 16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
- 17. Lohsiriwat V. Enhanced recovery after surgery for emergency colorectal surgery: Are there any differences between intra-abdominal infection and other indications? J Visc Surg. 2019;156:489-96.
- 18. Wisely JC, Barclay KL. Effects of an enhanced recovery after surgery programme on emergency surgical patients. ANZ J Surg. 2016;86:883-8.

- 19. Grass F, Pache B, Martin D, Addor V, Hahnloser D, Demartines N, et al. Feasibility of early postoperative mobilisation after colorectal surgery: A retrospective cohort study. Int J Surg. 2018;56:161-6.
- 20. Venara A, Barbieux J, Colas PA, Le Fouler A, Lermite E, Hamy A. Primary surgery for malignant large bowel obstruction: Postoperative nasogastric tube reinsertion is not mandatory. World J Surg. 2017;41:1903-9.
- 21. Barbieux J, Hamy A, Talbot MF, Casa C, Mucci S, Lermite E, et al. Does enhanced recovery reduce postoperative ileus after colorectal surgery? J Visc Surg. 2017;154:79-85.
- 22. Lau C, Phillips E, Bresee C, Fleshner P. Early use of low residue diet is superior to clear liquid diet after elective colorectal surgery: a randomized controlled trial. Ann Surg. 2014;260:641-7.
- 23. Zhang C, Yin S, Tan Y, Huang J, Wang P, Hou W, et al. Patient selection for adjuvant chemotherapy in high-risk stage II colon cancer: a systematic review and meta-analysis. Am J Clin Oncol. 2020.
- 24. Strouch MJ, Zhou G, Fleshman JW, Birnbaum EH, Hunt SR, Mutch MG. Time to initiation of postoperative chemotherapy: an outcome measure for patients undergoing laparoscopic resection for rectal cancer. Dis Colon Rectum. 2013;56:945-51.
- 25. Yoshida Y, Aisu N, Kojima D, Mera T, Kiyomi F, Yamashita Y, et al. Phase II study on early start of chemotherapy after excising primary colorectal cancer with distant metastases (Pearl Star 02). Ann Gastroenterol Surg. 2017;1:219-25.
- 26. Gao P, Huang XZ, Song YX, Sun JX, Chen XW, Sun Y, et al. Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study. BMC Cancer. 2018;18:234.
- 27. Lohsiriwat V, Jitmungngan R. Enhanced recovery after surgery in emergency colorectal surgery: Review of literature and current practices. World J Gastrointest Surg. 2019;11:41-52.
- 28. ERAS Compliance Group. The impact of enhanced recovery protocol compliance on elective colorectal cancer resection: Results from an international registry. Ann Surg. 2015;261:1153-9.
- 29. Vlug MS, Wind J, Hollmann MW, Ubbink DT, Cense HA, Engel AF, et al. Laparoscopy in combination with fast track multimodal management is the best perioperative strategy in patients undergoing colonic surgery: a randomized clinical trial (LAFA-study). Ann Surg. 2011;254:868-75.

Tables

Table 1 Main characteristics of the cohort studies included in the meta-analysis

	Lohsiriwat [10]	Shida et al. [11]	Shang et al. [12]
Country	Thailand	Japan	China
Study design	Retrospective cohort (matched-case control)	Retrospective cohort	Retrospective cohort (propensity score matching)
		(Pre vs Post-ERAS)	
Period of study	2011- 2013	2008 - 2012	2010 - 2017
conducted			
Year of	2014	2017	2018
publication			
Total number of	60 (20 vs 40)	122 (80 vs 42)	636 (318 vs 318)
patients (ERAS			
vs non-ERAS)			
Inclusion	Obstructive CRC	Obstructive CRC	Obstructive CRC
criteria			
Exclusion	No bowel resection, concomitant bowel	No bowel resection,	No bowel resection, concomitant bowel
criteria	perforation, recurrent tumor, neoadjuvant	concomitant bowel	perforation, recurrent tumor, gastrointestinal
	therapy	perforation	bleeding, neoadjuvant therapy, colonic stent
			utilization
Outcome(s)	LOHS, 30-day morbidity, 30-day mortality, 30-	LOHS, 30-day	LOHS, 30-day morbidity, GI recovery time, interval
	day readmission, GI recovery time, interval	morbidity, 30-day	between surgery and chemotherapy
	between surgery and chemotherapy	mortality, 30-day	
		readmission	
Average age	ERAS: 58	ERAS: 69	ERAS: 66
(years)	Non-ERAS: 62	Non-ERAS: 68	Non-ERAS: 65
Male (%)	ERAS: 70	ERAS: 65	ERAS: 60
	Non-ERAS: 60	Non-ERAS: 60	Non-ERAS: 63
Average BMI	ERAS: 21.7	n/a	ERAS: 25.1
(kg/m^2)	Non-ERAS: 22.8		Non-ERAS: 24.9
ASA class ≥ 3	ERAS: 20	n/a	ERAS: 32
(%)	Non-ERAS: 10		Non-ERAS: 31
Tumor location:	ERAS: 50, 40, 10	ERAS: 34, 50, 16	ERAS: 43, 45, 12
right colon, left	Non-ERAS: 47, 40, 13	Non-ERAS: 41, 45, 14	Non-ERAS: 45, 41, 14
colon, rectum			
(%)			
Pathological	ERAS: 70	ERAS: 60	ERAS: 69
staging ≥ 3 (%)	Non-ERAS: 65	Non-ERAS: 74	Non-ERAS: 71
Newcastle-	Selection: 4	Selection: 4	Selection: 4
Ottawa score	Comparability: 2	Comparability: 1	Comparability: 2
	Outcome: 3	Outcome: 3	Outcome: 3

Abbreviation: ASA = American society of Anesthesiologists, BMI = body mass index, CRC = colorectal cancer, ERAS = enhanced recovery after surgery, LOHS = length of hospital stay, n/a = not available

Figures




Figure 1

PRISMA flow diagram


(a) Length of hospital stay

	ERAS			Con	ventio	nal		Mean Difference		Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI				
Lohsiriwat 2014	6	2.9	20	9.4	5.1	40	17.1%	-3.40 [-5.43, -1.37]	2014					
Shida et al. 2017	7	1.3	80	10	3.2	42	69.0%	-3.00 [-4.01, -1.99]	2017					
Shang et al. 2018	6	14.1	318	9	14.8	318	13.9%	-3.00 [-5.25, -0.75]	2018					
Total (95% CI)			418			400	100.0%	-3.07 [-3.91, -2.23]		•				
Heterogeneity. Tau ² = 0.00; Chi ² = 0.12, df = 2 (P = 0.94); I^2 = 0% Test for overall effect: Z = 7.18 (P < 0.00001)										-4 -2 0 2 4 ERAS Conventional				

(b) Postoperative complication

	·		Risk Ratio		Risk Ratio
Study or Subgroup	log[Risk Ratio] SE	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Lohsiriwat 2014	-0.6931 0.7416	2.2%	0.50 [0.12, 2.14]	2014	
Shida et al. 2017	-0.3567 0.5053	4.7%	0.70 [0.26, 1.88]	2017	
Shang et al. 2018	-0.2274 0.1132	93.2%	0.80 [0.64, 0.99]	2018	
Total (95% CI)		100.0%	0.78 [0.63, 0.97]		•
Heterogeneity. Tau ² = Test for overall effect:	0.00; $Chi^2 = 0.44$, $df = 2$ Z = 2.23 (P = 0.03)		0.2 0.5 1 2 5		
			ERAS Conventional		

(c) 30-day readmission



(d) 30-day mortality




Figure 2

Forest plots of the comparisons of main surgical outcomes between ERAS and conventional care: (a) length of hospital stay, (b) postoperative complication, (c) 30-day readmission and (d) 30-day mortality. ERAS = enhanced recovery after surgery

(a) Time to pass flatus

	ERAS			Conventional				Mean Difference		Mean Difference					
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, F	Random,	, 95% CI			
Lohsiriwat 2014	1.6	0.7	20	2.8	1.3	40	7.2%	-1.20 [-1.71, -0.69]	2014						
Shang et al. 2018	1.2	0.8	318	2.6	1	318	92.8%	-1.40 [-1.54, -1.26]	2018						
Total (95% CI)			338			358	100.0%	-1.39 [-1.52, -1.25]		*					
Heterogeneity. Tau ² = 0.00; Chi ² = 0.56, df = 1 (P = 0.46); I^2 = Test for overall effect: Z = 20.03 (P < 0.00001)							= 0%			-2 -1	ERAS C	i conventional	2		

(b) Time to first defecation

	ERAS			Conv	entio	nal		Mean Difference	Mean Difference					
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV,	Random, 9	95% CI		
Lohsiriwat 2014	3.4	1.2	20	3.7	1.4	40	39.0%	-0.30 [-0.98, 0.38]						
Shang et al. 2018	2.5	1.5	318	3.5	1.4	318	61.0%	-1.00 [-1.23, -0.77]			-			
Total (95% CI)			338			358	100.0%	-0.73 [-1.40, -0.06]			•			
Heterogeneity. $Tau^2 = 0.18$; $Chi^2 = 3.65$, $df = 1$ (P = 0.06); $I^2 = 73\%$ Test for overall effect: Z = 2.13 (P = 0.03)								-4	-2	ERAS Co	2 nventional	4		

(c) Time to resume solid food





Figure 3

Forest plots of the comparisons of gastrointestinal recovery between ERAS and conventional care: (a) time to pass flatus, (b) time to first defecation and (c) time to resume solid food. ERAS = enhanced recovery after surgery

(a) Postoperative ileus

					Ri	sk Ratio				
Study or Subgroup	log[Risk Ratio]	SE	Weight	IV, Random, 95% CI	Year		IV, Ran	dom, 95%	í CI	
Lohsiriwat 2014	-1.2769	1.4879	3.0%	0.28 [0.02, 5.15]	2014			_	_	
Shida et al. 2017	-0.6109	0.2737	88.7%	0.54 [0.32, 0.93]	2017		-	⊪l		
Shang et al. 2018	-0.2389	0.8928	8.3%	0.79 [0.14, 4.53]	2018			-	_	
Total (95% CI)			100.0%	0.55 [0.33, 0.91]				▶		
Heterogeneity: Tau ² = Test for overall effect:	0.02	0.1	1	10	50					
rest for overall effect.	2 - 2.33 (r - 0.0		ER	AS Conve	ntional					

(b) Anastomotic leakage



(c) 30-day reoperation




Figure 4

Forest plots of the comparisons of postoperative morbidities between ERAS and conventional care: (a) postoperative ileus, (b) anastomotic leakage and (c) 30-day reoperation. ERAS = enhanced recovery after surgery




Figure 5

Forest plots of the comparisons of time to start adjuvant chemotherapy between ERAS and convention care. ERAS = enhanced recovery after surgery	al